Heart failure is a complex cardiovascular disorder with a variety of etiologies and heterogeneity with respect to the clinical presentation of the patient. New biomarkers are available that can assist in the prognosis for patients already diagnosed with heart failure, and can aid in risk stratification, earlier detection of treatment failure, and therapeutic targets.
The genetic aberrations present in multiple myeloma cells play a significant role in the risk stratification and therapeutic approach in multiple myeloma patients. Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART ) represents a consensus opinion on the utilization and assessment of these genetic markers in multiple myeloma.
Mayo Clinic has developed a novel diagnostic methodology that can subtype amyloidosis in routine biopsy specimens with high accuracy.
In this video, Dr. Roshini Abraham, Consultant in Clinical Biochemistry and Immunology, outlines the critical overlap between hematology practices and immunology testing. There are many times when it is critical for hematologists to discuss complex cases with clinical and laboratory immunologists including in the areas of test selection, genetic analysis and immune system monitoring. In particular, immunology testing is clinically and financially effective because it helps monitor the adequate numerical and functional recovery of the immune system.
To assist in the care of patients with newly diagnosed plasma cell myeloma, Mayo Medical Laboratories offers two tests that can help with plasma cell clonality determination and proliferation rate as well as targeted genetic analysis. Providing a high-level overview of this testing is Dr. Kaaren Reichard, Senior Associate Consultant in Hematopathology.
Lymphomas are among the most complex diseases to recognize and diagnose because they are pathologically complex, with features that overlap with reactive/inflammatory conditions and other nonhematologic malignancies. Dr. Paul Kurtin highlights Mayo Clinic’s highly experienced, 9-member hematopathology section focusing on lymphoma diagnosis, which diagnoses more than 3,000 lymphoma cases per year.
At least 25 different proteins have been shown to cause amyloidosis, and the underlying pathogenesis of each subtype of amyloidosis is unique. The treatment approach for each subtype of amyloidosis may be radically different. Dr. Paul Kurtin, Consultant in Hematopathology, outlines a novel diagnostic methodology developed at Mayo Clinic that can subtype amyloidosis in routine biopsy specimens with high accuracy.
Mayo Medical Laboratories offers comprehensive testing for plasma cell disorders. In this video, Dr. Kaaren Reichard, a Senior Associate Consultant in the Division of Hematopathology, provides an overview of two tests: Plasma Cell DNA Content and Proliferation and mSMART (Mayo Stratification for Myeloma And Risk-adapted Therapy).
Cancer screening tests — including the prostate-specific antigen (PSA) test to look for signs of prostate cancer — can be a good idea. Prostate cancer screening can help identify cancer early on, when treatment is most effective. And a normal PSA test, combined with a digital rectal exam, can help reassure you that it’s unlikely you have prostate cancer. But getting a PSA test for prostate cancer may not be necessary for some men, especially men 75 and older.